Kanomata Thomas I MD is categorized under Internal Medicine Doctors in Miamisburg, OH and active since 2003.
Kanomata Thomas I MD was established in 2003, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Internal Medicine Doctors business, which does work in the B2C market, and is classified as a Internal Medicine Doctors, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Thomas Kanomata at the company’s single location by writing to 4000 Miamisburg Ctrvl Road # 410, Miamisburg, Ohio OH 45342 or by phoning (937) 859-1117. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Kanomata Thomas I MD |
| Contact Person: | Thomas Kanomata |
| Address: | 4000 Miamisburg Ctrvl Road # 410, Miamisburg, Ohio 45342 |
| Phone Number: | (937) 859-1117 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2003 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Internal Medicine Doctors |
| SIC Code: | 8011 |
| NAICS Code: | 6211110 |
| Share This Business: |
Kanomata Thomas I MD was started in 2003 to provide professional Internal Medicine Doctors under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Thomas Kanomata for inquiries that concern Kanomata Thomas I MD by calling the company number (937) 859-1117, as your correspondence is most welcome. Additionally, the physical location of the single location of Kanomata Thomas I MD can be found at the coordinates 39.6282,-84.23167 as well as the street address 4000 Miamisburg Ctrvl Road # 410 in Miamisburg, Ohio 45342.
For its online presence, you may visit Kanomata Thomas I MD’s website at and engage with its social media outlets through on Twitter and on Facebook.